Cancer Biomarkers Market Report on Healthcare Trends by Diagnosis, Imaging, Immunoassay and Bioinformatics to 2023

Share this news:

Cancer Biomarkers Market analysis is provided for North America, Europe and Middle East market regions including development trends, competitive landscape analysis, key regions development status. Report provides a basic overview of industry including definitions, classifications, applications and industry chain structure.

Major factors driving growth of cancer biomakers market are rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies.

Cancer biomarkers market has evolved significantly owing to rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, & rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory & reimbursement scenario & high capital investments required for biomarker development & validation are some factors expected to restrain market.

Download Free PDF Brochure of Cancer Biomakers Market Report Now at .

The global cancer biomarkers market is accounted for USD 10.31 Billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 Billion by 2022 during the forecast period. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics.

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market.

Key Target Audience:
• Manufacturing companies of diagnostics kits and imaging instrument providers
• Biomarkers assay and reagent manufacturers, vendors, and distributors
• Contract research organizations (CROs)
• Companies offering platforms/technologies for cancer diagnosis
• Market research and consulting firms
• Venture capitalists and investors

Download Report with Discount - Cancer Biomarkers Market [267 Pages, 16 Companies Profiles] Now available at .

North America (comprising the US and Canada) is expected to account for largest share of cancer biomarkers market in 2017. The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.

Table of Content
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Cancer Biomarkers Market, By Biomarker Type
7 Cancer Biomarker Market, By Cancer Type
8 Cancer Biomarkers Market, By Profiling Technology
9 Cancer Biomarkers Market, By Application
10 Cancer Biomarkers Market, By Region
11 Competitive Landscape
12 Company Profiles

Major players in cancer biomakers market report are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).

More Information Now at .

Key Benefits of Buying the Report:
The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges). The report also offers market sizes and data on the growth of various segments of the industry.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–40%, Tier 2–30%, and Tier 3–30%
• By Designation–Director level–18%, C-Level–27%, and Others–55%
• By Region – North America–50%, Europe–20%, Asia-Pacific–20%, and RoW–10%

It focuses on emerging and high-growth segments, and high-growth regions. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future.

Contact Info:
Name: Snehal Shete
Email: Send Email
Organization: ReportsandReports
Address: Tower B5, Office 101, Magarpatta City SEZ, Pune-411013, India
Phone: +1 888 391 5441

Release ID: 483325